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Abstract
Endochondral ossification (EO) is the process by which the long bones of the body form and has proven to 
be a promising method in tissue engineering for achieving cell-mediated bone formation. The present review 
centred on state-of-the-art research pertaining to mesenchymal stem cells (MSCs)-mediated endochondral 
bone formation, focusing on the role of donor cells, extracellular matrix and host immune cells during 
tissue-engineered bone formation. Possible research avenues to improve graft outcome and bone output 
were highlighted, as well as emerging research that, when applied to tissue-engineered bone grafts, offers 
new promise for improving the likelihood of such grafts transition from bench to bedside.
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List of Abbreviations
ALP  alkaline phosphatase
ANG1  angiopoietin 1
BMP2  bone morphogenetic protein 2
CCN2  cellular communication network 
   factor 2
COLX  collagen type X
CTACK  cutaneous T-cell attracting
   chemokine
CTGF  connective tissue growth factor
DCs  dendritic cells
ECM  extracellular matrix
EO  endochondral ossification
FGF  fibroblast growth factor
GAG  glycosaminoglycan
GDF5  growth and differentiation factor 5
hPLAP  human placental alkaline
   phosphatase
HMGB1 high mobility group box 1
HSPG  heparin sulphate proteoglycan
Ihh  Indian hedgehog homologue
IL   interleukin
IMO  intramembranous ossification
KO  knock-out
MHC  major histocompatibility complex
MMPs  matrix metalloproteinases
MSC  mesenchymal stem cell/marrow
   stromal cell
NK  natural killer
PDGFA  platelet-derived growth factor
   subunit A
PLGA  poly(D,L-lactic-co-glycolic acid)
PRP  platelet-rich plasma
PTHrP  parathyroid hormone-related 
   protein
RANKL receptor activator of nuclear factor
   kappa-Β ligand
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Runx2  runt-related transcription factor 2
SMCD  Schmid metaphyseal
   chondrodysplasia disorder
TERM  tissue engineering and regenerative
   medicine
Tg   transgenic
TGF  transforming growth factor
TNFα  tumour necrosis factor alpha
VEGF  vascular endothelial growth factor
WNT  wingless-type MMTV integration
   site family
Introduction
Bone has an inherent ability to repair itself following 
small injuries (Schindeler et al., 2008). However, 
when a critical-size defect exists, or is created 
following surgery, the bone regenerative capacity is 
exhausted, making clinical intervention necessary. 
As a result, bone is one of the most commonly 
transplanted tissues in the world (Petite et al., 2000). 
Autologous bone grafts are the current gold-standard 
treatment option for such defects as they are a natural 
osteoinductive/osteoconductive material (Frohlich 
et al., 2008; Lieberman and Friedlaender, 2005) with 
low risk of immune rejection (Bauer and Muschler, 
2000). Although roughly 90 % of autologous grafts 
are considered to be successful (Bauer and Muschler, 
2000; Hayden et al., 2012), their use is limited due to 
the availability of harvestable material, uncertain 
integration following implantation and risk of donor 
site morbidity (Bauer and Muschler, 2000). Although 
allogeneic and xenogeneic grafts are available, they 
are associated with other risks, including disease 
transfer or immunological rejection (Gómez-Barrena 
et al., 2015). Common complications associated with 
bone grafts – regardless if autologous, allogeneic or 
xenogeneic – include insufficient vascularisation at 
the implant site, leading to poor nutrient/oxygen 
delivery, cell death and core necrosis (Frohlich et 
al., 2008; Lieberman and Friedlaender, 2005). This 
highlights a clear and present need for new suitable 
graft alternatives.
 TERM-based approaches to bone repair vary 
greatly (Grskovic et al., 2012). Bioactive or inert 
materials (Table 1), which should enhance bone 
regeneration by guided tissue regeneration, are 
currently being developed. Although promising, 
many of these materials and other TERM approaches 
also rely on the use of iliac crest bone, which does 
not address the many issues surrounding the use of 
autologous bone. The use of various adult progenitor 
cells to create cell-based alternatives recapitulating 
one of the developmental pathways of bone formation 
to achieve bone regeneration and repair of critical-size 
bone defects has received much attention in recent 
decades. This review focuses on the state-of-the-art 
strategies implemented in cell-based TERM and on 
considerations for improved bone regeneration and 
output.
Cell-based strategies for bone repair; 
endochondral vs. intramembranous ossification
Bone develops through either IMO (Kim et al., 2011) 
or EO (Shapiro, 2008; Yang et al. 2009). IMO involves 
the direct differentiation of mesenchymal cells to 
osteoblasts, the process by which most facial bones 
are formed (Thompson et al., 2002). IMO can be 
achieved in TERM by either direct differentiation or 
through the combination of MSCs with biomaterials 
(including, but not limited to, tricalcium phosphate 
or collagen sponges) (Meijer et al., 2008). Although 
promising, this approach has not reached its full 
potential due to insufficient vascularisation of the 
implant, resulting in core necrosis (Chatterjea et al., 
2010; Meijer et al., 2008). Vascularisation is crucial for 
graft survival and is required for proper integration 
with the patient’s existing bones. Instead, EO is 
a more promising model for bone formation as it 
naturally induces vascularisation at the implant 
site (Cervantes-Diaz et al., 2017; Gawlitta et al., 2010; 
Mackie et al., 2008; Medici and Olsen, 2012; Thompson 
et al., 2015; Yeung Tsang et al., 2014).
 EO relies on the establishment of a cartilage 
template, which is achieved by condensation and 
differentiation of mesenchymal cells (Mackie et al. 
2008). Chondrocytes within the template exhibit 
a zonal distribution, with clear divisions between 
the different stages of chondrocyte differentiation 
within the template. Resting chondrocytes display a 
seemingly sporadic distribution and are thought to 
maintain a population of cells which, when triggered, 
give rise to the more organised, disk-like proliferating 
chondrocytes (Schrier et al., 2006; Yang et al., 2003). 
Proliferating chondrocytes contribute to longitudinal 
bone growth and are regulated by a complicated 
feedback loop, including factors such as TGFβ, 
PTHrP and Ihh (Chen et al., 2008; Kronenberg et al., 
2003). These factors are also involved in initiating 
hypertrophic differentiation. When hypertrophic 
differentiation starts, chondrocytes secrete factors 
to recruit other cell types critical for successful EO 
(Ballock et al., 2003; Kronenberg et al., 2003) (Fig. 
1). For example, factors such as ANG-1, PDGFA 
and VEGF will aid in the recruitment of the nearby 
vasculature to the cartilage template (Colnot et al., 
2001), which will ultimately result in the delivery of 
pre-osteoblastic cells to the cartilage template (Maes 
et al., 2010). Factors released by the hypertrophic 
chondrocytes, including MMPs and other proteolytic 
enzymes, will contribute to early matrix remodelling 
(Nishimura et al., 2012); release of RANKL and VEGF 
will recruit osteoclasts, which further contribute 
to proper matrix remodelling (Engsig et al., 2000). 
Together, osteoblasts delivery through the invaded 
vasculature, trans-differentiation of chondrocytes in 
the cartilage template and osteoblast invasion from the 
surrounding bone collar calcify the cartilage matrix 
and bone formation occurs (Maes et al., 2010; Yang et 
al., 2014). The coordination of these events with cell/
vascular recruitment ultimately controls effective 
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bone formation in EO. This can be recapitulated in 
TERM by differentiating MSCs chondrogenically and 
implanting them subcutaneously either as pellets or 
seeded in scaffolds (Knuth et al., 2017; Scotti et al., 
2010; Tonnarelli et al., 2014; van der Stok et al., 2014). 
This seems to mirror developmental EO and shows 
excellent integration within the host tissue (Chan 
et al., 2009). Tissue-engineered EO, utilising MSCs, 
has been proven as a viable method to achieve bone 
formation (Dickhut et al., 2009; Hennig et al., 2007; 
Janicki et al., 2010; Jukes et al., 2008; Karoliina et al., 
2008) (Fig. 2). Huang et al. (2006) demonstrated the 
ability of chondrogenically-primed MSCs, loaded 
into a hyaluronan/gelatine scaffold, to form bone. 
Bahney et al. (2014) and van der Stok et al. (2014), 
each independently, demonstrated how these 
chondrogenic MSCs could also be used to partially 
repair a critical-size defect even without a biomaterial 
support. Interestingly, this has been shown to be 
specific for chondrogenically-differentiated MSCs, as 
chondrocytes following expansion and differentiation 
will not form bone or bone marrow in vivo despite 
similar culture characteristics. Whether this is 
associated with the developmental origin of these 
cells or their expression of specific proteins, such 
as COLX – a hypertrophy-associated collagen not 
expressed by culture-expanded chondrocytes – is 
unknown (Hellingman et al., 2011; Pelttari et al., 
2006; Pleumeekers et al., 2014). It is also possible that 
chondrocytes do not interact with cells of the host in 
a similar fashion. In order to develop better TERM 
approaches to bone defect repair recapitulating EO, 
understanding how MSC-mediated EO occurs and 
the kinetics of the process is necessary.
The donor’s role: recruitment of the host and 
long-term involvement
Induction of vascular invasion, de novo formation 
of a marrow cavity and osteoclast activity observed 
in tissue-engineered constructs have demonstrated 
that endogenous host cells have a role in new-bone 
formation (Farrell et al., 2011; Tasso et al., 2009; Tasso 
et al., 2010; Tortelli et al., 2010). Donor MSCs directly 
contribute to bone-forming cell populations in 
TERM EO. Using cell-labelling methods, implanted 
chondrogenically-differentiated MSCs have been 
shown to persist within the bone matrix and contribute 
directly to bone formation (Bahney et al., 2014; Farrell 
et al., 2011; Scotti et al., 2013). Farrell et al. (2011) 
suggested that the initial bone formation is mediated 
by donor MSCs. Using immunocompetent transgenic 
rats overexpressing hPLA, donor cells were tracked 
following implantation into syngeneic wild type rats. 
A mixed population of both positive and negative 
hPLAP cells found embedded within the bone matrix 
demonstrated that cells were of both donor and host 
origin. Scotti et al. (2013) further suggested that donor 
cells that persist in the newly formed bone may have 
undergone trans-differentiation to osteoblast-like 
cells. They reported that donor and host bone have 
a zonal distribution. Host cells contribute to bone 
formation in the outer periphery of the implant and 
donor cells in the central portion (Scotti et al., 2013). 
Although Scotti et al. (2013) hypothesised that over 
time these donor cells would be replaced by host 
cells, Bahney et al. (2014) suggested that most of 
the bone formation is donor-derived. This research 
contrasts with the developmental situation where it is 
Table 1. Bone-graft-related terminology and definitions/examples.
Term Definition Reference
Osteoinductive 
material
Can induce osteogenic differentiation of primitive cells; 
induces bone formation. Process that is observed during 
bone repair (healing).
Finkemeier, 2002
Lee, 2016
Osteoconductive 
material
Causes bone formation on the surface of a material; induces 
migration of bone-forming cells to the surface of the 
material; observed regularly on bone implants; examples: 
hydroxyapatite, tricalcium phosphate.
Finkemeier, 2002
Lee, 2016
Inert material Not chemically active; material does not join/integrate 
directly with bone; example: titanium, steel.
LeGeros, 2008
Roselló Llabrés et al., 
Bioactive 
material
Causes a biological response allowing for tissue bonding to 
the material; surface reactivity influences ability to bond to 
bone; example: bioactive glass and ceramics.
Ducheyne et al., 1999
Allogeneic graft
Tissue or cells obtained from donor material of same species 
as recipient; osteoinductive and osteoconductive; can be 
fresh or frozen.
Roselló Llabrés et al., 
2014
Autologous 
graft
Tissue or cells obtained from patient receiving treatment; 
osteoinductive and osteoconductive.
Roselló Llabrés et al., 
2014
Xenogenic graft Tissue or cells obtained from a non-human source; example: 
bovine, porcine.
Roselló Llabrés et al., 
2014
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bone formation following implantation. Knuth 
et al. (2017) reported how stronger chondrogenic 
induction can influence in vivo bone formation; 
however, they hypothesised that a more GAG-
rich matrix delays bone marrow formation due to 
delayed remodelling. Perhaps this indicates that 
parameters, using ECM components produced by 
chondrogenically-differentiated MSCs, can be set 
to assess bone formation; nevertheless, performing 
this without destroying the pellet would be difficult. 
Recently, Correa et al. (2015) have suggested that 
chondrogenic potential can be influenced through 
the addition of certain FGFs which modulate TGFβ 
receptors, in turn altering GAG concentration. If so, 
researchers could utilise this approach to alter GAG 
production within the pre-implantation constructs. 
However, research in this area has yielded conflicting 
data and how TGFβ receptor modulation influence 
ECM production by MSCs is still an area of ongoing 
investigation (Correa et al., 2015; de Kroon et al., 2015).
 When trying to further understand how the 
ECM influences EO, valuable insight comes also 
from the use of chondrogenically-differentiated 
MSCs, not to achieve EO but as a tissue engineering 
cartilage replacement. Chondrocytes formed through 
differentiation of MSCs as compared to native 
chondrocytes exhibit clear differences in structure, 
ECM deposition, cellular phenotypes and mechanical 
properties (as reviewed by Somoza et al., 2018). 
Researchers are investigating how they can prevent 
tissue-engineering MSC cartilage constructs from 
forming bone in vivo. For instance, suppression of 
canonical WNT signalling during chondrogenic 
differentiation results in less hypertrophic constructs, 
containing less COLX in the ECM, which has a 
negative effect on bone formation in vivo (Narcisi et 
believed that following hypertrophic differentiation 
of chondrocytes, apoptosis is their only fate, as shown 
in previous avian-based research (Gibson et al., 1995). 
Recently, this theory has been challenged. Studies 
in development, fracture repair and TERM showed 
that hypertrophic chondrocytes do not all undergo 
apoptosis. Rather, a subset of them are plastic and 
capable of transdifferentiating into osteoblasts or 
osteoblast-like cells, further aiding in the process 
of bone formation (Bahney et al., 2014; Yang et al., 
2014; Zhou et al., 2014). From a developmental 
point of view, Yang et al. (2014) showed that these 
transdifferentiated hypertrophic chondrocytes persist 
throughout development, being present not only 
in foetal bone but also in the bone of adult mice. 
These finds have changed how researchers view 
bone homeostasis in development and in TERM 
since chondrocytes do contribute to bone formation. 
In tissue engineering, there is a trend towards 
development of acellular grafts which are, indeed, 
attractive from a clinical perspective. However, 
knowing that implanted cells play an important role 
in bone formation, it may be necessary to rethink 
such approaches in order to maximise bone output. 
Certainly, in more challenging clinical situations.
The role of the ECM in MSC-mediated EO
During chondrogenic differentiation of MSCs, a 
bioactive matrix is produced which can greatly 
influence EO in vivo. Studies have suggested that the 
quality of the pre-implantation matrix influences in 
vivo bone formation. Scotti et. al (2010) reported that 
after longer priming, more chondrogenic induction 
and GAG production is achieved, resulting in better 
Fig. 1. Snapshot of cellular invasion and behaviour during developmental EO. Following the establishment 
of the cartilage template, a specific subset of hypertrophic chondrocytes undergoes apoptosis. This creates 
space for the nearby vasculature to invade and release bioactive molecules within the matrix. At the same 
time, pericytic-like pre-osteoblasts, attached to the side of the vasculature, invade it by passive migration. 
Factors released from the degraded ECM further aid in the recruitment of matrix-remodelling osteoclasts. 
The non-apoptotic chondrocytes found within the matrix are capable of trans-differentiating into osteoblast-
like cells that, in combination with mature osteoblasts, contribute to bone formation.
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al., 2015). This may indicate that, for improved bone 
formation, the enhancement of the WNT signalling 
pathway during chondrogenic differentiation would 
have a beneficial effect on ECM and cell behaviour 
for bone repair. Importantly, Narcisi et al. (2015) 
also highlighted the importance of hypertrophic 
differentiation for the induction of bone formation 
with MSC-based endochondral grafts.
 Developmentally, hypertrophic differentiation 
precedes mineralisation and, during this phase, 45 % 
of the collagens produced is COLX (Luvalle et al., 
1992). COLX adds to the structural stability in the 
surrounding pericellular network of hypertrophic 
chondrocytes (Schmid and Linsenmayer, 1985; Shen, 
2005) but, from a bone formation stand point, its 
role can be more clearly seen in Tg and KO studies. 
In such studies, perinatal death is reported in the 
absence of COLX (around 25 % in Tg mice and 10 % 
in KO mice), with the surviving mice exhibiting a 
range of phenotypes including dwarfism, skeletal 
abnormalities, defective haematopoiesis or normal 
phenotype (Campbell et al., 2004; Jacenko et al., 2001; 
Jacenko et al., 2002; Kwan et al., 1997). The absence 
of COLX has an impact on the normal skeletal 
development in mice, but the exact mechanisms 
contributing to each of these abnormalities needs to 
be further explored to truly understand how COLX 
contributes to bone formation and the supportive 
role it plays during the process. In the absence of 
COLX, abnormal GAG distribution and decreased 
HSPG content around hypertrophic chondrocytes is 
reported (Jacenko et al., 2001). Proper proteoglycan 
distribution throughout the remodelled matrix is 
essential as it not only plays a role in stabilising the 
ECM, but also regulates the availability of growth 
factors trapped within the matrix that are crucial 
for EO, contributing to induction of blood vessel 
invasion and attraction of matrix remodelling cells, 
such as osteoclasts, in a timely manner (Kim et al., 
2011; Yang et al., 2012). Proper ECM arrangement 
is not only important with regards to the above-
mentioned aspects but also for proper placement of 
smaller structures, such as matrix vesicles.
 Matrix vesicles are small structures that bud from 
the membrane of chondrocytes, osteoblasts and other 
cells. These structures carry with them, among other 
things, a collection of bioactive enzymes, proteins 
and phospholipids, specific to the cell they are 
produced from, that are important in the initiation 
of calcification (Anderson et al., 2005; Golub, 2009; 
Lohan et al., 2017). Matrix vesicles become entrapped 
in the ECM and help attract cells through their content 
(i.e. VEGF to attract blood vessels, BMPs to attract 
osteoblasts, etc.), making their point of anchoring and 
zonal distribution crucial for proper cell recruitment 
to the correct area (Kirsch et al., 2000; Nahar et al., 
2008). Research has focussed on the interactions 
between COLX and annexin V, which is found on 
matrix vesicles. Annexin V facilitates calcium influx 
into matrix vesicles, which is important for the 
initiation of biomineralisation within the vesicles, 
in turn influencing matrix mineralisation and bone 
formation. COLX can selectively bind to annexin 
V, initiating this influx of calcium into the matrix 
vesicles (Kirsch and Pfäffle, 1992; Wu et al., 1991). 
Others reported that when COLX is absent, vesicle 
distribution throughout the matrix is disrupted 
and subsequent bone formation is stunted (Kwan 
Fig. 2. Achieving tissue engineered EO. (a) MSCs are expanded to reach the required cell number 
through cell passage. Then, MSCs are chondrogenically-differentiated, usually through the addition of 
TGFβ, dexamethasone and vitamin C (here a chondrogenic pellet is shown in the red circle). Following 
differentiation, the resulting chondrocytes are implanted in an animal model for a predetermined time. 
Following implantation, the resulting construct can be retrieved and analysed (constructs in white 
circles). (b) Representative MSCs during expansion phase. (c) A representative thionine staining of MSCs 
chondrogenically-differentiated for 21 d trough pellet culture. (d) Haemotoxylin and eosin staining showing 
representative bone formed from chondrogenically-differentiated MSCs after 8 weeks of subcutaneous 
implantation in nude mice (B-bone, CC-calcified cartilage, BM-bone marrow). 
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et al., 1997; Wu et al., 1991). This is alarming and 
shows that proper placement of matrix vesicles is 
required for cell attraction to the proper site of bone 
formation. However, this conclusion is challenged 
by others in the field who found that knocking out 
annexin V results in no change in mineralisation 
or bone formation (Grskovic et al., 2012). Although 
initially these results appear to be contradictory, there 
could be a simple explanation. COLX plays a role in 
supporting and maintaining ECM proteoglycan and 
collagen organisation. When COLX is absent, these 
are no longer properly organised. Matrix vesicles also 
associate with the hyaluronic-acid-binding region 
found in proteoglycans, which can also result in 
calcium influx (Wu et al., 1991). If COLX is absent, 
matrix vesicles can possibly associate more strongly 
with proteoglycans, allowing them to be entrapped 
in the matrix, possibly no longer specifically, at the 
border of the chondro-osseous junction, but still 
able to initiate mineralisation, thus allowing bone 
formation to still take place.
 EO also influences proper development of the 
bone marrow niche and proper haematopoiesis, 
which studies have suggested is also partially 
regulated by COLX. Cytokines, chemokines and 
growth factors bind and interact with HSPG, in 
part regulating or controlling an immune response 
(Sweeney et al., 2008; Wu et al., 1991). COLX 
decrease correlates with a decrease in HSPG and 
a dysregulation of the immune system of Tg mice. 
Additionally, an increase in factors that play a role 
in regulating immune responses – including IL-4, IL-
12, CTACK and leptin, which all bind to HSPG – and 
major changes to the immune system itself are shown. 
Mice with defective or missing COLX often have a 
severely decreased immune cell count. Although the 
immune cells that remain in the mouse often function 
properly, the immune response they elicit cannot be 
controlled, ultimately leading to death in immune-
challenge studies (Sweeney et al., 2008). When mice 
with defective/missing COLX are challenged with 
an opportunistic parasite, they can initially clear the 
parasitic infection but do not recover and ultimately 
die. Post-mortem investigation shows enlarged livers 
and increased parasite cysts in the brain, liver and 
lungs, both indicative of a malfunctioned immune 
response (Sweeney et al., 2008). With a decreased 
HSPG count and an increased production of 
immune factors, the body is unable to regulate the 
response properly. Researchers have argued over 
the importance of COLX in regulating the immune 
response, as conflicting results have been shown 
(Kwan et al., 1997; Rosatil et al., 1994). However, the 
differences observed between researchers may also 
come down to the genetic profile of the models they 
used.
Osteoimmunology from a tissue engineering 
perspective
In large bone defects, the cells of the immune system 
play an important role. The complex interaction 
between cells of the skeletal system and the immune 
system is critical for successful bone repair and 
is initiated by an inflammatory response to the 
damaged tissue (Dar et al., 2018; Kolar et al., 2010; 
Mountziaris and Mikos, 2008; Pape et al., 2010). This 
leads to the secretion of pro-inflammatory cytokines, 
including TNFα, IL-6 and IL-1β (Gerstenfeld et al., 
2003; Mountziaris and Mikos, 2008). These cytokines 
can induce angiogenesis and attract cells of the innate 
immune response (monocytes, macrophages, DCs, 
neutrophils and NK cells). Subsequently, those cells 
release specific cytokines and growth factors which 
attract cells of the adaptive immune system (T and 
B cells) (Kovach et al., 2015). Immune cells are not 
the only cells attracted during this inflammatory 
Fig. 3. T cells can influence 
osteoblastic and osteoclastic 
maturation. The release 
of cytokines and various 
growth factors during bone 
formation and fracture repair 
results in the recruitment of 
various immune cells which 
can influence bone formation 
and remodelling (green 
arrow: positive influence, red 
bar line: negative influence).
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response. Bone-specific growth factors such as 
TGFβ and BMP-2 are also secreted, leading to the 
recruitment of osteoprogenitor cells (including MSCs) 
to the site of inflammation (Kovach et al., 2015). 
The combined expression of growth factors with 
secretion of inflammatory mediators induces the 
proliferation and differentiation of osteoprogenitor 
cells to osteoblasts (Dimitriou et al., 2011; Loi et 
al., 2016; Mizuno et al., 1990). IMO and EO are the 
two processes by which osteoprogenitor cells can 
differentiate to osteoblasts. Unlike in IMO, during 
EO, the secretion of TGFβ2 or 3, BMPs and other 
signalling molecules, each of which can be influenced 
by immune cells, leads to the formation of a cartilage 
template that is replaced by woven bone (Brighton, 
1984; Einhorn and Gerstenfeld, 2015; Gerstenfeld et 
al., 2003; Kolar et al., 2010; Kuntzman, 2010). Most 
fractures heal through EO and previous studies 
have demonstrated the importance of the immune 
system during the repair process; lymphocytes, in 
particular, are crucial for fracture healing (Schindeler 
et al., 2008). During bone remodelling, infiltrating 
T and B cells into the fracture callus are negatively 
involved in the bone repair process (Konnecke et al., 
2014; Young et al., 2005). During bone remodelling, 
Th1, Th2 and regulatory T cells negatively influence 
osteoclast maturation; however, Th17 cells show a 
positive effect on osteoclast formation (Takayanagi, 
2009; Walsh et al., 2018; Zaiss et al., 2007). Mice 
lacking T and B cells appear to have accelerated 
fracture healing as compared to those with a fully 
competent immune system (Toben et al., 2011). More 
specifically, CD8 T cells inhibit fracture repair (Reinke 
et al., 2013). However, on the other hand, other T cells 
have varying effects on bone formation/regeneration 
depending on the studied subtype (Lei et al., 2015; 
Nam et al., 2012; Young et al., 2005). Collectively, the 
complex interaction between the immune system 
and the cells of the skeletal system is critical for 
the outcome of the bone repair/regeneration as the 
manipulation of a specific subset of immune cells 
could greatly impact bone formation.
 The use of autologous cells for bone regeneration 
is ideal due to the lack of immune rejection upon 
implantation. However, autologous cells have the 
drawback of the limited quantity of material that can 
be obtained. Moreover, the material that is obtained 
is usually of poor quality. This is due to the fact that 
autologous cell transplantation is generally needed in 
elderly and diseased patients and, therefore, having 
cells with poor proliferative and differentiation 
capacities as compared to those that could be 
obtained from healthy individuals (Mueller and 
Glowacki, 2001). Furthermore, treating patients with 
their own cells can cause a major delay in treatment 
timetables due to in vitro cell manipulations (e.g. 
expansion and quality control) before cells can be 
administered back into the patient. Taking this into 
consideration, new and improved TERM-based 
approaches to bone repair need to be developed. 
The use of allogeneic cells would be preferable as 
there would be an immediate approved stock of cells 
ready to treat a patient. This advantage has led to an 
increased research interest aiming at using allogeneic 
cells for TERM applications. Research on allogeneic 
MSCs has demonstrated that they are somewhat 
immunoevasive, due to low surface expression of 
costimulatory molecules (e.g. CD80 and CD86) and 
MHC class II (Aggarwal and Pittenger, 2005; Ankrum 
et al., 2014; Le Blanc and Ringden, 2007; Nauta and 
Fibbe, 2007). Such an aspect is advantageous as MSCs 
will be implanted into an inflammatory environment 
during fracture repair (Ankrum et al., 2014; Asari 
et al., 2009; Corcione et al., 2006; Djouad et al., 2007; 
Jiang et al., 2005; Sotiropoulou et al., 2006; Spaggiari 
et al., 2009; Spaggiari et al., 2008; Zhao et al., 2012; 
Zheng et al., 2008). In normal situations, implantation 
of allogeneic cells would lead to cell rejection by 
the adaptive immune system. However, allogeneic 
MSCs can evade the immune response and in some 
instances avoid rejection upon implantation (Ankrum 
et al., 2014; Ryan et al., 2005). In studies focussed on the 
use of allogeneic MSCs for bone repair, the immune 
response has been shown to play an important role in 
the process. Bone regeneration induced by allogeneic 
MSCs is negatively impacted by Th1 cells through the 
inhibition of osteogenesis-specific gene expression 
(osteocalcin, Runx2 and ALP) (Dighe et al., 2013). 
On the other hand, osteogenesis is promoted by Th2, 
Th17 and regulatory T cells (Kovach et al., 2015; Liu 
et al., 2011; Omar et al., 2011). While there have been 
numerous studies on allogeneic undifferentiated 
MSCs, little investigation has been carried on how the 
immune system responds to allogeneic MSCs when 
they are pre-differentiated into another tissue type 
prior to implantation. Allogeneic undifferentiated 
MSCs have been shown to be non-immunogenic 
(Aggarwal and Pittenger, 2005; English, 2013; Gao 
et al., 2016; Hoogduijn et al., 2010; Nauta and Fibbe, 
2007). Due to their immunoevasive nature, they can 
modify the immune system to their desired purpose. 
Few studies have investigated the effects of allogeneic 
chondrogenic MSCs on the immune system. Thus 
far, results have been conflicting, with reports 
demonstrating allogeneic chondrogenic MSCs to 
be both immunogenic (Mukonoweshuro et al., 2014; 
Ryan et al., 2014) and non-immunogenic (Adkisson 
et al., 2010; Kiernan et al., 2016; Le Blanc et al., 2003; 
Zheng et al., 2008).
 The contradictory results were highly dependent 
on how the co-culturing work was performed during 
the experiments. Even in the in vivo setting, little is 
known about the effects of these pre-differentiated 
MSCs on the immune system. Kiernan et al. (2016) 
have recently detailed the various studies that have 
focussed on the interactions between the immune 
system and allogeneic differentiated MSCs in the 
context of bone tissue engineering. More recently, 
the immune-privileged nature of allogeneic MSCs 
has been called into question. As reviewed by Griffin 
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et al. (2013) and Lohan et al. (2017), host responses 
vary in response to the presence of allogeneic MSCs 
from minor inflammation to right out rejection. The 
idea that allogeneic MSCs could be recognised and 
targeted by the host is concerning for many in the field 
of tissue engineering. It is clear from these studies that 
there is more research that needs to be conducted to 
determine how pre-differentiated MSCs interact with 
the immune system in an allogeneic setting before 
these cells can be used clinically. However, it appears 
increasingly unlikely that MSCs or differentiated 
MSCs are truly incapable of completely evading 
the immune system. The question to be answered is 
whether this is an issue to be concerned about.
Further considerations, towards improved
 bone output
MSC-mediated endochondral bone formation has 
yielded some promising results in animal model 
defect repair; however, treatment of large bone 
defects is still problematic. Although Harada et 
al. (2014) showed how chondrogenically-primed 
rat MSCs could heal a critical-size defect, no other 
group has demonstrated such large bone defect 
repair. Although MSC-mediated EO can form bone 
in vivo, the quantity usually formed, outside Harada 
et al. (2014) study, is insufficient to treat large bone 
defects. From a translational perspective, the volume 
of chondrogenic MSCs required to properly heal 
critical-size defects would require unmanageable 
cell numbers, incubator space, reagents and time 
to maintain, which would make the cost of such 
constructs astronomical (Penick et al., 2005; van der 
Stok et al., 2014). In order to treat large defects, scale-
up approaches are necessary to improve bone output.
 When considering scaled-up bone formation, 
the need for successful vascularisation to maintain 
cell health during regeneration must be considered. 
As most cells of the body are rarely more than 100-
200 µm away from a capillary, due to diffusion limits 
influencing their behaviour (Biederman-Thorson et 
al., 2013; Ko et al., 2007), proper vascularisation in 
TERM constructs is critical. Although chondrocytes 
are thought to be well suited to survive in the initial 
defect site, as their true environment is also hypoxic 
and avascular (Pfander and Gelse, 2007), remodelling, 
vessel invasion and bone formation introduce new 
cells with variable oxygen/nutrient requirements into 
the defect site (Ko et al., 2007), making vascularisation 
crucial to ensure these cells’ survival. In small defect 
repair, vascularisation occurs rapidly enough to 
allow graft survival and integration; however, with 
a large defect, natural vascularisation rates may not 
be sufficient. Therefore, vascularisation must be 
induced or compensated for in the initial implanted 
construct to prevent cell death. Pre-vascularisation 
of chondrogenic grafts pre-implantation has shown 
more promising results (Ng et al., 2017; Yousefi et 
al., 2016). Freeman et al. (2015) showed that the pre-
vascularisation of chondrogenic MSCs can result in 
accelerated vascularisation, host cell survival and 
ossification versus non-vascularised counterparts. 
These constructs were implanted for only 4 weeks 
but it would be interesting to see how constructs 
perform following longer in vivo implantation or 
in immunocompetent animals. These studies are 
promising but special care must be taken when 
selecting endothelial cell sources since the phenotype 
of the cell differs depending on the tissue type they 
are isolated from (Chi et al., 2003; Garlanda and 
Dejana, 1997). Takigawa (2013) investigated how 
the addition of biologically relevant compounds 
known to influence endothelial cell behaviour, 
such as VEGF, could be utilised for improving graft 
vascularisation. However, high doses of VEGF result 
in uncontrollable bone formation, indicating further 
research is required to make this a more viable option 
(Maes et al., 2010). By accelerating processes which 
are known to be important for in vivo bone formation, 
such as vascularisation, it could be possible to, not 
only improve graft performance, but also increase 
bone formation, as bone-forming osteocytes can 
invade the cartilage template migrating through the 
vasculature (Maes, 2013; Maes et al., 2010). From a 
TERM approach, pre-vascularising grafts or inducing 
faster vascularisation is advantageous to not only 
tackle the issue of poor vascularisation but also to 
increase bone formation in the process.
 Given the complications associated with cell-
based approaches for tissue regeneration, there is 
the attempt to find possible cell-free approaches, 
which could circumvent these limitations. MSCs 
used in endochondral tissue engineering bone grafts 
directly contribute to the bone-forming population 
(Bahney et al., 2014; Farrell et al., 2011; Mendes et al., 
2018; Scotti et al., 2013). Implanted chondrogenically-
differentiated MSCs persist within the bone matrix 
and contribute directly to bone formation, instructing 
host bone formation throughout the process (Bahney 
et al., 2014; Farrell et al., 2011; Mendes et al., 2018; 
Scotti et al., 2013). These studies have suggested 
that implanted cells are essential for proper bone 
formation; however, devitalised grafts derived from 
chondrogenically-differentiated MSCs can also 
form endochondral bone in vivo (Bourgine, 2013; 
Bourgine et al., 2014a; Bourgine et al., 2014b; Cunniffe 
et al., 2015). Bourgine et al. (2013; 2014a; 2014b) 
created decellularised grafts which maintain bone 
formation potential once implanted. They utilised 
immortalised cell lines – eliminating many of the 
culture-induced issues associated with MSCs – which 
are decellularised through activation of an engineered 
death-inducible receptor within the cell. Once 
decellularised and implanted, these constructs show 
promising bone formation ability. Moreover, these 
immortalised cells could be further manipulated 
to overexpress factors known to improve bone 
formation, such as BMP2, which, in turn, would be 
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incorporated in the ECM and could further improve 
bone output. Cunniffe et al. (2015), following this 
same line of research, showed that matrices produced 
specifically by hypertrophic chondrogenically-
differentiated MSCs produced significantly more 
bone than non-hypertrophic matrices, indicating 
that something not yet identified but produced 
specifically during hypertrophy could be the key to 
improved bone formation. Although bone formed 
by acellular grafts produced significantly less bone 
volume than cellularised counterparts, these cell-free 
grafts are still able to recruit host vasculature and cells 
required for proper bone formation (Bourgine, 2013; 
Bourgine et al., 2014a). With further optimisation, 
they could be a promising alternative to current 
autologous bone grafts. Although decellularised 
grafts and off-the-shelf treatment options are an 
ideal solution for tissue engineering, it remains that 
current cell-based approaches yield better bone 
formation than acellular counterparts. As such, a 
popular scale-up approach consists of using growth 
factors combined with novel biomaterials. Growth 
factors important for developmental induction of 
EO, such as BMP-2 (Decambron et al., 2017; Penick 
et al., 2005; Stüdle et al., 2018), TGFβ (Mendes et al., 
2018; Stüdle et al., 2018), VEGF (Carlevaro et al., 2000; 
Gerber et al., 1999), PRP (Janssen et al., 2013) as well 
as potentially novel factors (Fahmy-Garcia et al., 2017) 
are being characterised to determine if their use in 
combination with MSCs would improve bone output. 
The use of these factors has shown variable results, 
performing as well as, better or worse than iliac crest 
bone (Janssen et al., 2013). Two drawbacks associated 
with this approach are that these factors are extremely 
expensive and are used at supraphysiological levels, 
which is associated with additional risk. For example, 
high doses of BMP-2 can cause soft tissue swelling 
(Shahlaie and Kim, 2008), abnormal excessive bone 
formation (Zara et al., 2011) and increased cancer 
risk (Carragee et al., 2013). As such, researchers 
are also investigating other compounds which are 
known to be involved in EO and could possibly 
be used at more physiologically acceptable doses. 
This includes GDF5. This protein is well known 
for its role in joint formation, chondrogenesis and 
hypertrophic differentiation and is also a member 
of a subgroup of BMPs (Coleman et al., 2013). Other 
proteins which are more recently identified as being 
important during EO, including CTGF (also known 
as CCN2) and HMGB1, have also been investigated 
as possible additions to improve bone formation as 
they have shown positive results in vitro for improved 
cell recruitment, vascularisation and osteogenesis 
(Khattab et al., 2015; Kubota and Takigawa, 2011; 
Takigawa, 2013; Taniguchi et al., 2007). Such proteins 
could be used at more physiologically relevant doses 
as compared to BMP-2 (Fahmy-Garcia et al., 2017). 
However, even when supraphysiological doses 
are required, researchers are looking for ways to 
possibly decrease the effective dosage required to 
prevent these unwanted side effects. By coupling or 
crosslinking factors to matrices, the concentration 
of these compounds can be reduced to something 
more physiologically acceptable (Mumcuoglu et al., 
2018; Quinlan et al., 2015). Further research into the 
identification of new biologically relevant compounds 
is also useful. Recent studies have identified new stem 
cell populations which are activated in response to 
acute skeletal injury (Chan et al., 2018). By studying 
the secreted profile of these cells in comparison with 
controls, new relevant targets could be identified 
which may not even require supraphysiological doses 
to be effective. Additionally, the use of organs-on-a-
chip and other computational models, which have 
been proven promising to identify/validate targets 
and have improved screening methods (Esch et al., 
2015), could accelerate results and research.
Conclusions
Modelling grafts in tissue engineering after EO 
has been an active area of research in bone tissue 
engineering for years. The initial cartilage graft is 
well suited to survive in an avascular environment 
and it can induce, on its own, the migration of all 
the previously mentioned cell types. Although 
it is a reproducible method for bone formation, 
progress to enhance the bone-forming capacity of 
these constructs, to properly fill large bone defects, 
is moving slowly. However, as the understanding of 
the interactions that take place improves – not only 
between donor and host cells but also those of a fully 
functioning immune system – a better appreciation of 
how to improve such grafts will follow. As research in 
the field continues, graft vascularisation, integration 
and bone output will improve, making these tissue-
engineered endochondral grafts a viable alternative 
to autologous bone graft substitutes in the future.
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Discussion with Reviewer
Diego Correa: Taking into consideration the 
pericytic phenotype of MSCs and their description as 
osteoprogenitors during bone formation and fracture 
healing (Maes et al., 2010), what would be the real 
contribution of such cells (as perivascular) during 
the engineering of bone grafts?
Authors: The idea that perictyic MSCs attach to the 
side of the vasculature, in a way effectively and 
passively migrating to the site of bone formation, 
is one of our favourite theories in bone tissue 
engineering. Although Maes et al. (2010) show that 
these cells undergo osteoblastic differentiation and 
contribute to bone formation, we believe they could 
also contribute to a number of crucial processes, 
considering the many bioactive molecules they 
encounter in this environment which can influence 
their behaviour. It would be interesting to see if 
they also contribute to the stabilisation of the bone 
marrow niche microenvironment or somehow further 
influence the migration of the vasculature into the 
centre of the cartilage template. We fully believe they 
contribute to bone formation, but as the field digs 
deeper into this area, they may find these cells play 
an even bigger role in bone formation.
Diego Correa: If such a phenomenon results critical, 
how do the authors envision to enhance it?
Authors: If it proves critical that pericytic MSCs, 
specifically the subset that co-migrate with the 
invading vasculature, are crucial for bone formation, 
it could be advantageous to enhance or accelerate 
the migration of the vasculature. Alternatively, 
determining what factor(s) this specific subset of 
MSCs is attracted to would be better; then, this(these) 
could be incorporated into a tissue-engineered 
construct or bound to a biomaterial to enhance 
migration of this specific MSC subtype which would 
have the potential to improve or accelerate bone 
formation.
Editor’s note: The Scientific Editor responsible for 
this paper was Martin Stoddart.
